| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics |
Neurosystems Center and Departments of Preventive Sciences, Psychiatry, and Neuroscience [N. M. L., P. H., M. C. S., M. J. S., S. D. R., D. B. M., P. W. M.], Department of Orthopedic Surgery [D. R. C.], and Cancer Center [N. M. L., P. H., M. C. S., M. J. S., S. D. R., D. B. M., D. R. C., P. W. M.], University of Minnesota, Minneapolis, Minnesota 55455, and VA Medical Center, Minneapolis, Minnesota 55417 [N. M. L., P. H., M. C. S., M. J. S., S. D. R., D. B. M., P. W. M.]
Bone cancer pain most commonly occurs when tumors originating in breast, prostate, or lung metastasize to long bones, spinal vertebrae, and/or pelvis. Primary and metastatic cancers involving bone account for approximately 400,000 new cancer cases per year in the United States alone, and >70% of patients with advanced breast or prostate cancer have skeletal metastases. Whereas pain resulting from bone cancer can dramatically impact an individual’s quality of life, very little is known about the mechanisms that generate and maintain this pain. To begin to define the mechanisms that give rise to advanced bone cancer pain, osteolytic 2472 sarcoma cells or media were injected into the intramedullary space of the femur of C3H/HeJ mice, and the injection hole was sealed using dental amalgam, confining the tumor cells to the bone. Twelve days after injection of 2472 tumor cells, animals showed advanced tumor-induced bone destruction of the injected femur, bone cancer pain, and a stereotypic set of neurochemical changes in the spinal cord dorsal horn that receives sensory inputs from the affected femur. Administration of osteoprotegerin, a naturally secreted decoy receptor that inhibits osteoclast maturation and activity and induces osteoclast apoptosis, or vehicle was begun at 12 days, when significant bone destruction had already occurred, and administration was continued daily until day 21. Ongoing pain behaviors, movement-evoked pain behaviors, and bone destruction were assessed on days 10, 12, 14, 17, and 21. The neurochemistry of the spinal cord was evaluated at days 12 and 21. Results indicated that osteoprotegerin treatment halted further bone destruction, reduced ongoing and movement-evoked pain, and reversed several aspects of the neurochemical reorganization of the spinal cord. Thus, even in advanced stages of bone cancer, ongoing osteoclast activity appears to be involved in the generation and maintenance of ongoing and movement-evoked pain. Blockade of ongoing osteoclast activity appears to have the potential to reduce bone cancer pain in patients with advanced tumor-induced bone destruction.
This article has been cited by other articles:
|
|
 |
|
  M. K. Crook and T. A. Guise RANKL: Targeting Bone and Cancer to Treat Skeletal Complications of Malignancy IBMS BoneKEy, September 1, 2009; 6(9): 323 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Delaney, S. M. Fleetwood-Walker, L. A. Colvin, and M. Fallon Translational medicine: cancer pain mechanisms and management Br. J. Anaesth., July 1, 2008; 101(1): 87 - 94. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Lamoureux, P. Richard, Y. Wittrant, S. Battaglia, P. Pilet, V. Trichet, F. Blanchard, F. Gouin, B. Pitard, D. Heymann, et al. Therapeutic Relevance of Osteoprotegerin Gene Therapy in Osteosarcoma: Blockade of the Vicious Cycle between Tumor Cell Proliferation and Bone Resorption Cancer Res., August 1, 2007; 67(15): 7308 - 7318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Benoliel, J. Epstein, E. Eliav, R. Jurevic, and S. Elad Orofacial Pain in Cancer: Part I--Mechanisms Journal of Dental Research, June 1, 2007; 86(6): 491 - 505. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Goblirsch, P. Zwolak, M. L. Ramnaraine, W. Pan, C. Lynch, P. Alaei, and D. R. Clohisy Novel Cytosine deaminase fusion gene enhances the effect of radiation on breast cancer in bone by reducing tumor burden, osteolysis, and skeletal fracture. Clin. Cancer Res., May 15, 2006; 12(10): 3168 - 3176. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Spohn, K. Schwarz, P. Maurer, H. Illges, N. Rajasekaran, Y. Choi, G. T. Jennings, and M. F. Bachmann Protection against Osteoporosis by Active Immunization with TRANCE/RANKL Displayed on Virus-Like Particles J. Immunol., November 1, 2005; 175(9): 6211 - 6218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. G. Halvorson, K. Kubota, M. A. Sevcik, T. H. Lindsay, J. E. Sotillo, J. R. Ghilardi, T. J. Rosol, L. Boustany, D. L. Shelton, and P. W. Mantyh A Blocking Antibody to Nerve Growth Factor Attenuates Skeletal Pain Induced by Prostate Tumor Cells Growing in Bone Cancer Res., October 15, 2005; 65(20): 9426 - 9435. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Ghilardi, H. Rohrich, T. H. Lindsay, M. A. Sevcik, M. J. Schwei, K. Kubota, K. G. Halvorson, J. Poblete, S. R. Chaplan, A. E. Dubin, et al. Selective Blockade of the Capsaicin Receptor TRPV1 Attenuates Bone Cancer Pain J. Neurosci., March 23, 2005; 25(12): 3126 - 3131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Urch The pathophysiology of cancer-induced bone pain: current understanding Palliative Medicine, June 1, 2004; 18(4): 267 - 274. [Abstract] [PDF]
|
|
|
|
 |
|
 M. P. Goetz, M. R. Callstrom, J. W. Charboneau, M. A. Farrell, T. P. Maus, T. J. Welch, G. Y. Wong, J. A. Sloan, P. J. Novotny, I. A. Petersen, et al. Percutaneous Image-Guided Radiofrequency Ablation of Painful Metastases Involving Bone: A Multicenter Study J. Clin. Oncol., January 15, 2004; 22(2): 300 - 306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Guzman, M. G. Evans, S. Bove, B. Morenko, and K. Kilgore Mono-Iodoacetate-Induced Histologic Changes in Subchondral Bone and Articular Cartilage of Rat Femorotibial Joints: An Animal Model of Osteoarthritis Toxicol Pathol, October 1, 2003; 31(6): 619 - 624. [Abstract] [PDF]
|
|
|
|
|
|
U. Heider, C. Langelotz, C. Jakob, I. Zavrski, C. Fleissner, J. Eucker, K. Possinger, L. C. Hofbauer, and O. Sezer Expression of Receptor Activator of Nuclear Factor {kappa}B Ligand on Bone Marrow Plasma Cells Correlates with Osteolytic Bone Disease in Patients with Multiple Myeloma Clin. Cancer Res., April 1, 2003; 9(4): 1436 - 1440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Sezer, U. Heider, I. Zavrski, C. A. Kuhne, and L. C. Hofbauer RANK ligand and osteoprotegerin in myeloma bone disease Blood, March 15, 2003; 101(6): 2094 - 2098. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Dirajlal, L. E. Pauers, and C. L. Stucky Differential Response Properties of IB4-Positive and -Negative Unmyelinated Sensory Neurons to Protons and Capsaicin J Neurophysiol, January 1, 2003; 89(1): 513 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Beckman The Burden of Pain on the Shoulders of Aging Sci. Aging Knowl. Environ., December 18, 2002; 2002(50): oa1 - 1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. C. Sabino, J. R. Ghilardi, J. L. M. Jongen, C. P. Keyser, N. M. Luger, D. B. Mach, C. M. Peters, S. D. Rogers, M. J. Schwei, C. de Felipe, et al. Simultaneous Reduction in Cancer Pain, Bone Destruction, and Tumor Growth by Selective Inhibition of Cyclooxygenase-2 Cancer Res., December 15, 2002; 62(24): 7343 - 7349. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
